CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) [Yahoo! Finance]
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock, up previously from $2.50.
CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling [Seeking Alpha]
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? [Yahoo! Finance]